Cancer Vaccines Market Overview
Cancer vaccines are medicines considered as biological response modifiers. These biological response modifiers work by stimulating the immune system of the body to fight against cancer. Preventive cancer vaccines and therapeutic cancer vaccines are two types of cancer vaccines. The increasing number of cancer patients across the world is the key factor to boost the growth of the global Cancer Vaccines market. According to National Cancer Institute, Cancer is among the leading causes of death worldwide. In 2018, there were 18.1 million new cases and 9.5 million cancer-related deaths worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.5 million and the number of cancer-related deaths to 16.4 million.
Moreover, other factors which are reasonable to fuel the growth of the global Cancer Vaccines market are the rising old age population, surge in patient awareness towards cancer therapy, and increase in cancer vaccines usage combined with other therapies. Additionally, an increase in investments and government funding in the development of cancer vaccines by manufacturers are the major factors that drive the growth of the Cancer Vaccines market. As well, technological developments in cancer vaccines, the launch of novel cancer vaccines, rise in health care services, and expenditure further remarkably contribute to the Cancer Vaccines market’s expansion.
On the other hand, the high cost for developing cancer vaccines and the longer period required for manufacturing a single vaccine are anticipated to hamper the growth of the market.
Covid-19 Impact on Cancer Vaccines Market
In addition, the current Cancer Vaccines Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Cancer Vaccines Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Cancer Vaccines Market Segment Overview
Based on technology, the recombinant cancer vaccines segment has the largest share of the market and is projected to maintain its supremacy over the forecast period. An increase in adoption of recombinant technology, rise in utilization of recombinant vaccines, and surge in the number of approved cancer vaccines developed using recombinant technology are the crucial factors that boost the growth of this segment. Additionally, by indication, the Cervical Cancer segment has the maximum share of the global cancer vaccines market. This is due to the high prevalence of cervical cancer and the increase in the number of people suffering from human papilloma virus (HPV) infections. In addition, drug development in the field of cervical cancer, and an increase in patient awareness toward cervical cancer propel the growth of this segment.
Cancer Vaccines Market, By Technology
· Dendritic Cells (DC) Cancer Vaccines
· Recombinant Cancer Vaccines
· Antigen/Adjuvant Cancer Vaccines
· Viral Vector & DNA Cancer Vaccines
Cancer Vaccines Market, By Indication
· Cervical Cancer
· Prostate Cancer
· Others
Cancer Vaccines Market, By Type
· Preventive Cancer Vaccines
· Therapeutic Cancer Vaccines
Cancer Vaccines Market, By End-User
· Adults
· Children
Cancer Vaccines Market Regional Overview
Region-wise, North America dominates the Cancer Vaccines market owing to a major market share of the U.S. Similarly, Asia Pacific is expected to expand with an impressive CAGR over the forecast period. This is mainly due to rising government initiatives, increased focus of players on the vaccine technology market in India, and rising immunization initiatives by the World Health Organization and GAVI. In addition to this, rising adoption of cancer vaccines, an increasing number of cancer patients in developing countries, rising healthcare reforms, and technological advancements in cancer vaccines are other factors that majorly contribute to the growth of the Cancer Vaccines market in this region.
Cancer Vaccines Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Cancer Vaccines Market Competitor overview
Some key developments and strategies adopted by manufacturers in Cancer Vaccines are highlighted below.
· In July 2021, Using nanotechnology, a team of researchers in China have designed personalised tumour vaccines based on bacterial cytoplasmic membranes and cell membranes from resected tumour tissue. These scientists said that these vaccines could potentially offer an opportunity for the development of individualised cancer vaccines to fight against a broad range of tumours.
Cancer Vaccines Market, Key Players
· AstraZeneca plc
· Prima Sanofi
· BioMed
· GlaxoSmithKline
· Merck
· Aduro BioTech
· OncoThyreon
· Oxford BioMedica
· Advaxis Inc.
· Amgen Inc.
· Dynavax Technologies Corporation
· Generex Biotechnology Corporation
· Immunocellular Therapeutics, Ltd
· Sanpower Group Co. Ltd.
· UbiVac
· Vaccinogen, Inc.
Cancer vaccines are medicines considered as biological response modifiers. These biological response modifiers work by stimulating the immune system of the body to fight against cancer. Preventive cancer vaccines and therapeutic cancer vaccines are two types of cancer vaccines. The increasing number of cancer patients across the world is the key factor to boost the growth of the global Cancer Vaccines market. According to National Cancer Institute, Cancer is among the leading causes of death worldwide. In 2018, there were 18.1 million new cases and 9.5 million cancer-related deaths worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.5 million and the number of cancer-related deaths to 16.4 million.
Moreover, other factors which are reasonable to fuel the growth of the global Cancer Vaccines market are the rising old age population, surge in patient awareness towards cancer therapy, and increase in cancer vaccines usage combined with other therapies. Additionally, an increase in investments and government funding in the development of cancer vaccines by manufacturers are the major factors that drive the growth of the Cancer Vaccines market. As well, technological developments in cancer vaccines, the launch of novel cancer vaccines, rise in health care services, and expenditure further remarkably contribute to the Cancer Vaccines market’s expansion.
On the other hand, the high cost for developing cancer vaccines and the longer period required for manufacturing a single vaccine are anticipated to hamper the growth of the market.
Covid-19 Impact on Cancer Vaccines Market
In addition, the current Cancer Vaccines Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Cancer Vaccines Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Cancer Vaccines Market Segment Overview
Based on technology, the recombinant cancer vaccines segment has the largest share of the market and is projected to maintain its supremacy over the forecast period. An increase in adoption of recombinant technology, rise in utilization of recombinant vaccines, and surge in the number of approved cancer vaccines developed using recombinant technology are the crucial factors that boost the growth of this segment. Additionally, by indication, the Cervical Cancer segment has the maximum share of the global cancer vaccines market. This is due to the high prevalence of cervical cancer and the increase in the number of people suffering from human papilloma virus (HPV) infections. In addition, drug development in the field of cervical cancer, and an increase in patient awareness toward cervical cancer propel the growth of this segment.
Cancer Vaccines Market, By Technology
· Dendritic Cells (DC) Cancer Vaccines
· Recombinant Cancer Vaccines
· Antigen/Adjuvant Cancer Vaccines
· Viral Vector & DNA Cancer Vaccines
Cancer Vaccines Market, By Indication
· Cervical Cancer
· Prostate Cancer
· Others
Cancer Vaccines Market, By Type
· Preventive Cancer Vaccines
· Therapeutic Cancer Vaccines
Cancer Vaccines Market, By End-User
· Adults
· Children
Cancer Vaccines Market Regional Overview
Region-wise, North America dominates the Cancer Vaccines market owing to a major market share of the U.S. Similarly, Asia Pacific is expected to expand with an impressive CAGR over the forecast period. This is mainly due to rising government initiatives, increased focus of players on the vaccine technology market in India, and rising immunization initiatives by the World Health Organization and GAVI. In addition to this, rising adoption of cancer vaccines, an increasing number of cancer patients in developing countries, rising healthcare reforms, and technological advancements in cancer vaccines are other factors that majorly contribute to the growth of the Cancer Vaccines market in this region.
Cancer Vaccines Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Cancer Vaccines Market Competitor overview
Some key developments and strategies adopted by manufacturers in Cancer Vaccines are highlighted below.
· In July 2021, Using nanotechnology, a team of researchers in China have designed personalised tumour vaccines based on bacterial cytoplasmic membranes and cell membranes from resected tumour tissue. These scientists said that these vaccines could potentially offer an opportunity for the development of individualised cancer vaccines to fight against a broad range of tumours.
Cancer Vaccines Market, Key Players
· AstraZeneca plc
· Prima Sanofi
· BioMed
· GlaxoSmithKline
· Merck
· Aduro BioTech
· OncoThyreon
· Oxford BioMedica
· Advaxis Inc.
· Amgen Inc.
· Dynavax Technologies Corporation
· Generex Biotechnology Corporation
· Immunocellular Therapeutics, Ltd
· Sanpower Group Co. Ltd.
· UbiVac
· Vaccinogen, Inc.
Cancer Vaccines Market Study Global Market Analysis, Insights and Forecast, 2020-2027
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Cancer Vaccines Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Technology
- 5.2.1. Dendritic Cells (DC) Cancer Vaccines
- 5.2.2. Recombinant Cancer Vaccines
- 5.2.3. Antigen/Adjuvant Cancer Vaccines
- 5.2.4. Viral Vector & DNA Cancer Vaccines
- 5.3. Market Analysis, Insights and Forecast – By Indication
- 5.3.1. Cervical Cancer
- 5.3.2. Prostate Cancer
- 5.3.3. Others
- 5.4. Market Analysis, Insights and Forecast – By Type
- 5.4.1. Preventive Cancer Vaccines
- 5.4.2. Therapeutic Cancer Vaccines
- 5.5. Market Analysis, Insights and Forecast – By End-User
- 5.5.1. Adults
- 5.5.2. Children
- 5.6. Market Analysis, Insights and Forecast – By Region
- 5.6.1. North America
- 5.6.2. Europe
- 5.6.3. Asia Pacific
- 5.6.4. Latin America, Middle East and Africa
6. North America Cancer Vaccines Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Technology
- 6.2.1. Dendritic Cells (DC) Cancer Vaccines
- 6.2.2. Recombinant Cancer Vaccines
- 6.2.3. Antigen/Adjuvant Cancer Vaccines
- 6.2.4. Viral Vector & DNA Cancer Vaccines
- 6.3. Market Analysis, Insights and Forecast – By Indication
- 6.3.1. Cervical Cancer
- 6.3.2. Prostate Cancer
- 6.3.3. Others
- 6.4. Market Analysis, Insights and Forecast – By Type
- 6.4.1. Preventive Cancer Vaccines
- 6.4.2. Therapeutic Cancer Vaccines
- 6.5. Market Analysis, Insights and Forecast – By End-User
- 6.5.1. Adults
- 6.5.2. Children
- 6.6. Market Analysis, Insights and Forecast – By Country
- 6.6.1. U.S.
- 6.6.2. Canada
7. Europe Cancer Vaccines Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Technology
- 7.2.1. Dendritic Cells (DC) Cancer Vaccines
- 7.2.2. Recombinant Cancer Vaccines
- 7.2.3. Antigen/Adjuvant Cancer Vaccines
- 7.2.4. Viral Vector & DNA Cancer Vaccines
- 7.3. Market Analysis, Insights and Forecast – By Indication
- 7.3.1. Cervical Cancer
- 7.3.2. Prostate Cancer
- 7.3.3. Others
- 7.4. Market Analysis, Insights and Forecast – By Type
- 7.4.1. Preventive Cancer Vaccines
- 7.4.2. Therapeutic Cancer Vaccines
- 7.5. Market Analysis, Insights and Forecast – By End-User
- 7.5.1. Adults
- 7.5.2. Children
- 7.6. Market Analysis, Insights and Forecast – By Country
- 7.6.1. UK
- 7.6.2. Germany
- 7.6.3. France
- 7.6.4. Italy
- 7.6.5. Spain
- 7.6.6. Russia
- 7.6.7. Rest of Europe
8. Asia Pacific Cancer Vaccines Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Technology
- 8.2.1. Dendritic Cells (DC) Cancer Vaccines
- 8.2.2. Recombinant Cancer Vaccines
- 8.2.3. Antigen/Adjuvant Cancer Vaccines
- 8.2.4. Viral Vector & DNA Cancer Vaccines
- 8.3. Market Analysis, Insights and Forecast – By Indication
- 8.3.1. Cervical Cancer
- 8.3.2. Prostate Cancer
- 8.3.3. Others
- 8.4. Market Analysis, Insights and Forecast – By Type
- 8.4.1. Preventive Cancer Vaccines
- 8.4.2. Therapeutic Cancer Vaccines
- 8.5. Market Analysis, Insights and Forecast – By End-User
- 8.5.1. Adults
- 8.5.2. Children
- 8.6. Market Analysis, Insights and Forecast – By Country
- 8.6.1. China
- 8.6.2. India
- 8.6.3. Japan
- 8.6.4. Australia
- 8.6.5. South East Asia
- 8.6.6. Rest of Asia Pacific
9. Latin America, Middle East and Africa Cancer Vaccines Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Technology
- 9.2.1. Dendritic Cells (DC) Cancer Vaccines
- 9.2.2. Recombinant Cancer Vaccines
- 9.2.3. Antigen/Adjuvant Cancer Vaccines
- 9.2.4. Viral Vector & DNA Cancer Vaccines
- 9.3. Market Analysis, Insights and Forecast – By Indication
- 9.3.1. Cervical Cancer
- 9.3.2. Prostate Cancer
- 9.3.3. Others
- 9.4. Market Analysis, Insights and Forecast – By Type
- 9.4.1. Preventive Cancer Vaccines
- 9.4.2. Therapeutic Cancer Vaccines
- 9.5. Market Analysis, Insights and Forecast – By End-User
- 9.5.1. Adults
- 9.5.2. Children
- 9.6. Market Analysis, Insights and Forecast – By Country
- 9.6.1. Brazil
- 9.6.2. Saudi Arabia
- 9.6.3. UAE
- 9.6.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. AstraZeneca plc
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. Prima Sanofi
- 10.6. BioMed
- 10.7. GlaxoSmithKline
- 10.8. Merck
- 10.9. Aduro BioTech
- 10.10. OncoThyreon
- 10.11. Oxford BioMedica
- 10.12. Advaxis Inc.
- 10.13. Amgen Inc.
- 10.14. Dynavax Technologies Corporation
- 10.15. Generex Biotechnology Corporation
- 10.16. Immunocellular Therapeutics, Ltd
- 10.17. Sanpower Group Co. Ltd.
- 10.18. UbiVac
Research Process
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
